Raplixa Purple Book BLA 125523

BLA number
125523
Proprietary names
Raplixa
Proper names
Fibrin Sealant (Human)
Applicant
Mallinckrodt Pharma IP Trading DAC
Center
CBER
First observed release
2022-05-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001RaplixaFibrin Sealant (Human)351(a)0.5GPowderTopicalVialDiscVoluntarily Revoked2015-04-30
002RaplixaFibrin Sealant (Human)351(a)1GPowderTopicalVialDiscVoluntarily Revoked2015-04-30
003RaplixaFibrin Sealant (Human)351(a)2GPowderTopicalVialDiscVoluntarily Revoked2015-04-30

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2023-06-01U001Raplixa351(a)DiscMallinckrodt Pharma IP Trading DAC
2023-06-01U002Raplixa351(a)DiscMallinckrodt Pharma IP Trading DAC
2023-06-01U003Raplixa351(a)DiscMallinckrodt Pharma IP Trading DAC
2022-05-01N001Raplixa351(a)RxMallinckrodt Pharma IP Trading DAC
2022-05-01N002Raplixa351(a)RxMallinckrodt Pharma IP Trading DAC
2022-05-01N003Raplixa351(a)RxMallinckrodt Pharma IP Trading DAC

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2023-06-01001Raplixa351(a)DiscVoluntarily Revoked2015-04-30
2023-06-01002Raplixa351(a)DiscVoluntarily Revoked2015-04-30
2023-06-01003Raplixa351(a)DiscVoluntarily Revoked2015-04-30
2022-05-01001Raplixa351(a)RxVoluntarily Revoked2015-04-30
2022-05-01002Raplixa351(a)RxVoluntarily Revoked2015-04-30
2022-05-01003Raplixa351(a)RxVoluntarily Revoked2015-04-30